| Ticker Details |
Eli Lilly & Co.
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
|
| IPO Date: |
January 2, 1990 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$853.33B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.05 | 0.95%
|
| Avg Daily Range (30 D): |
$12.30 | 1.28%
|
| Avg Daily Range (90 D): |
$13.74 | 1.34%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
4.32M |
| Avg Daily Volume (30 D): |
2.17M |
| Avg Daily Volume (90 D): |
2.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
112 |
| Avg Trade Size (Sh.) (30 D): |
19 |
| Avg Trade Size (Sh.) (90 D): |
20 |
| Institutional Trades |
| Total Institutional Trades: |
87,600 |
| Avg Institutional Trade: |
$10.24M |
| Avg Institutional Trade (30 D): |
$86.88M |
| Avg Institutional Trade (90 D): |
$98.33M |
| Avg Institutional Trade Volume: |
.07M |
| Avg Institutional Trades (Per Day): |
15 |
| Market Closing Trades |
| Avg Closing Trade: |
$92.51M |
| Avg Closing Trade (30 D): |
$456.25M |
| Avg Closing Trade (90 D): |
$463M |
| Avg Closing Volume: |
415.43K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$23
|
$7.4
|
$23
|
|
Diluted EPS
|
$22.95
|
$7.39
|
$22.95
|
|
Revenue
|
$65.18B
|
$19.29B
|
$65.18B
|
|
Gross Profit
|
$54.13B
|
$15.92B
|
$54.13B
|
|
Net Income / Loss
|
$20.64B
|
$6.64B
|
$20.64B
|
|
Operating Income / Loss
|
$25.73B
|
$8.27B
|
$25.73B
|
|
Cost of Revenue
|
$11.05B
|
$3.37B
|
$11.05B
|
|
Net Cash Flow
|
$4B
|
$-2523.5M
|
$4B
|
|
PE Ratio
|
40.96
|
|
|
|
|
|
